Glenn has over 30 years in experience in global infectious disease and with a focus in anti-infective drug development and medical educational and medical affairs. Glenn has written many publications in the various aspects of ID (>150 papers on PubMed with a further >40 not cited). Demonstrated capabilities in broad-ranging educational initiatives aimed at improving patient health. Glenn has published multiple publications and an e-book on C difficile. Recently he has been active in developing new products for Clostridium difficile, MRSA and MDR Gram-negative infections. Built and led a medical affairs team to prepare for the approval and launch of a fourth-generation macrolide for use in pneumonia. Most recently played a role in the approval of cefiderocol ,a novel siderophore cephalosporin, in the US.
We look forward to Dr. Tillitson collaborating with members of the Infection Prevention and Control Committee to develop continued strategy for Infection Prevention & Control and to join the decision making IPC committee members to ensure that the Infection Prevention & Control Annual Conference Program material is agreed, developed and implemented for the good of fellow-healthcare professionals worldwide.